[go: up one dir, main page]

WO2008118324A3 - Composition et procédé de traitement du cancer avec un anticorps anti-uroplakine ib - Google Patents

Composition et procédé de traitement du cancer avec un anticorps anti-uroplakine ib Download PDF

Info

Publication number
WO2008118324A3
WO2008118324A3 PCT/US2008/003635 US2008003635W WO2008118324A3 WO 2008118324 A3 WO2008118324 A3 WO 2008118324A3 US 2008003635 W US2008003635 W US 2008003635W WO 2008118324 A3 WO2008118324 A3 WO 2008118324A3
Authority
WO
WIPO (PCT)
Prior art keywords
uroplakin
antibody
composition
treating cancer
upk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/003635
Other languages
English (en)
Other versions
WO2008118324A2 (fr
Inventor
Stacy Ferguson
Scott Koenig
Nadine Tuaillon
Leslie S Johnson
Ling Huang
Christopher Rankin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macrogenics Inc
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of WO2008118324A2 publication Critical patent/WO2008118324A2/fr
Publication of WO2008118324A3 publication Critical patent/WO2008118324A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des anticorps qui reconnaissent et se lient spécifiquement à UPK-Ib. L'invention comprend également des dosages diagnostiques et thérapeutiques pour les maladies associées à des niveaux non régulés d'UPK-Ib, basés sur lesdits anticorps. Ces anticorps et leurs dérivés peuvent également être utiles dans le diagnostic et/ou le traitement des cancers associés à une expression anormale d'UPK-Ib.
PCT/US2008/003635 2007-03-26 2008-03-20 Composition et procédé de traitement du cancer avec un anticorps anti-uroplakine ib Ceased WO2008118324A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92026107P 2007-03-26 2007-03-26
US60/920,261 2007-03-26

Publications (2)

Publication Number Publication Date
WO2008118324A2 WO2008118324A2 (fr) 2008-10-02
WO2008118324A3 true WO2008118324A3 (fr) 2008-12-18

Family

ID=39789179

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/003635 Ceased WO2008118324A2 (fr) 2007-03-26 2008-03-20 Composition et procédé de traitement du cancer avec un anticorps anti-uroplakine ib

Country Status (1)

Country Link
WO (1) WO2008118324A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
WO2019143961A2 (fr) * 2018-01-19 2019-07-25 The Trustees Of The University Of Pennsylvania Compositions et méthodes de ciblage de lymphocytes t gamma delta au moyen de récepteurs antigéniques chimériques
WO2022132929A2 (fr) * 2020-12-16 2022-06-23 Vera Therapeutics, Inc. Molécules d'anticorps multispécifiques et leurs utilisations

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
CA1291031C (fr) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Methode pour la detection de liants specifiques et des substances liables par ceux-ci
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5001065A (en) 1987-05-27 1991-03-19 Cetus Corporation Human cell line and triomas, antibodies, and transformants derived therefrom
US5563250A (en) 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
US5141648A (en) 1987-12-02 1992-08-25 Neorx Corporation Methods for isolating compounds using cleavable linker bound matrices
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
DE69130709T3 (de) 1990-10-05 2005-12-22 Celldex Therapeutics, Inc. Gezielte immunostimulierung mit bispezifischen stoffen
DE69128253T2 (de) 1990-10-29 1998-06-18 Chiron Corp Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
IE921342A1 (en) 1991-04-26 1992-11-04 Surface Active Ltd Novel antibodies, and methods for their use
WO1992020373A1 (fr) 1991-05-14 1992-11-26 Repligen Corporation Anticorps d'heteroconjugues pour le traitement des infections a l'hiv
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
CA2078539C (fr) 1991-09-18 2005-08-02 Kenya Shitara Procede de fabrication de chimere d'anticorps humain
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
CA2452130A1 (fr) 1992-03-05 1993-09-16 Francis J. Burrows Agents diagnostiques et/ou therapeutiques cibles pour les cellules endotheliales neovasculaires
WO1993021319A1 (fr) 1992-04-08 1993-10-28 Cetus Oncology Corporation ANTICORPS HUMANISES SPECIFIES PAR C-erbB-2
CA2140280A1 (fr) 1992-08-17 1994-03-03 Avi J. Ashkenazi Immunoadhesines bispecifiques
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
WO1994012520A1 (fr) 1992-11-20 1994-06-09 Enzon, Inc. Segment de liaison pour polypeptides fusionnes lies
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5691447A (en) 1995-03-24 1997-11-25 Tanox Biosystems, Inc. GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
KR100654645B1 (ko) 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
WO1996040662A2 (fr) 1995-06-07 1996-12-19 Cellpro, Incorporated Composes de liaison contenant un groupe aminooxy et leur utilisation pour la formation de conjugues
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
PT1500329E (pt) 1996-12-03 2012-06-18 Amgen Fremont Inc Anticorpos humanos que se ligam especificamente ao tnf alfa humano
RU2224766C2 (ru) 1997-04-14 2004-02-27 Микромет Аг Способ получения рецепторов для человеческих антигенов и их применение
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
NZ539776A (en) 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001096584A2 (fr) 2000-06-12 2001-12-20 Akkadix Corporation Matieres et procedes de lutte contre les nematodes
AU2002357932A1 (en) 2001-12-18 2003-06-30 Whitehead Institute For Biomedical Research Fusion partner cells and uses thereof
EP1534335B9 (fr) 2002-08-14 2016-01-13 Macrogenics, Inc. Anticorps specifiques du recepteur fcgammariib et procedes d'utilisation de ces anticorps
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2368578A1 (fr) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification et ingénierie d'anticorps avec régions FC de variante et procédés d'utilisation associés
WO2007024249A2 (fr) 2004-11-10 2007-03-01 Macrogenics, Inc. Fonction effectrice obtenue par creation par genie biologique de regions d'anticorps fc
EP1868650B1 (fr) 2005-04-15 2018-10-03 MacroGenics, Inc. Di-anticorps covalents et leurs utilisations
CA2618681C (fr) 2005-08-10 2015-10-27 Macrogenics, Inc. Identification et ingenierie d'anticorps presentant des zones de variants fc et procedes d'utilisation de ces anticorps

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HU CHIH-CHI ANDREW ET AL: "Assembly of urothelial plaques: tetraspanin function in membrane protein trafficking.", MOLECULAR BIOLOGY OF THE CELL SEP 2005, vol. 16, no. 9, September 2005 (2005-09-01), pages 3937 - 3950, XP002500449, ISSN: 1059-1524 *
LOBBAN E D ET AL: "Uroplakin gene expression by normal and neoplastic human urothelium.", THE AMERICAN JOURNAL OF PATHOLOGY DEC 1998, vol. 153, no. 6, December 1998 (1998-12-01), pages 1957 - 1967, XP000882577, ISSN: 0002-9440 *
MAHBUB HASAN A K M ET AL: "Uroplakin III, a novel Src substrate in Xenopus egg rafts, is a target for sperm protease essential for fertilization.", DEVELOPMENTAL BIOLOGY 15 OCT 2005, vol. 286, no. 2, 15 October 2005 (2005-10-15), pages 483 - 492, XP002500448, ISSN: 0012-1606 *
OLSBURGH JONATHON ET AL: "Human uroplakin lb gene structure and promoter analysis.", BIOCHIMICA ET BIOPHYSICA ACTA 7 JUN 2002, vol. 1576, no. 1-2, 7 June 2002 (2002-06-07), pages 163 - 170, XP004356760, ISSN: 0006-3002 *

Also Published As

Publication number Publication date
WO2008118324A2 (fr) 2008-10-02

Similar Documents

Publication Publication Date Title
WO2010032059A3 (fr) Agents de liaison ciblés dirigés sur cd105 et leurs utilisations
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
MX338754B (es) Anticuerpos humanos contra el factor tisular.
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
WO2008112003A3 (fr) Agents liants cibles diriges contre pdgfr-alpha et utilisations associees
WO2009013543A3 (fr) Agents de liaisons ciblés dirigés vers kdr, et utilisations de ceux-ci - 035
ATE526987T1 (de) Dr5-antikörper und deren verwendung
WO2007084181A3 (fr) Molécules d'anticorps fv à chaîne unique bispécifiques et procédés d'utilisation de celles-ci
WO2008140493A3 (fr) Anticorps de la famille anti-egfr, anticorps de la famille anti-egfr bispécifiques et leurs procédés d'utilisation
WO2008134724A3 (fr) Procédés d'administration d'anticorps anti-il-5
WO2011143318A3 (fr) Anticorps anti-fgfr2
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
NZ595235A (en) Compositions and methods for increasing muscle growth
TN2010000092A1 (en) Humanized cxcr5 antidodies, derivatives thereof and their uses
JO2576B1 (en) Antibodies
WO2010059969A3 (fr) Thérapie antiangiogenèse pour le traitement du cancer du sein
WO2007053573A3 (fr) Traitement du cancer au moyen de sorafenib
IL197148A (en) Antibodies and preparations for the treatment of antibodies caused by antibodies
WO2012177595A9 (fr) Compositions et méthodes pour la thérapie et le diagnostic du cancer
WO2009070294A3 (fr) Inhibition du récepteur de la protéine stimulant les macrophages (ron) et procédés de traitement
WO2008150530A3 (fr) Molécules de liaison de cripto
WO2007135546A3 (fr) TRAITEMENT DU CANCER PAR DES ANTICORPS ANTI-IL-1α
WO2008151819A3 (fr) Traitement de tumeurs à l'aide d'un anticorps anti-l1 spécifique
WO2009142738A3 (fr) Compositions et procédés utilisables en matière de diagnostic et de traitement du cancer
WO2010072740A3 (fr) Agents de liaison ciblés dirigés contre α5β1 et leurs applications

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08742141

Country of ref document: EP

Kind code of ref document: A2